These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 26895387)

  • 1. Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity.
    Kwarcinski FE; Brandvold KR; Phadke S; Beleh OM; Johnson TK; Meagher JL; Seeliger MA; Stuckey JA; Soellner MB
    ACS Chem Biol; 2016 May; 11(5):1296-304. PubMed ID: 26895387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What Makes a Kinase Promiscuous for Inhibitors?
    Hanson SM; Georghiou G; Thakur MK; Miller WT; Rest JS; Chodera JD; Seeliger MA
    Cell Chem Biol; 2019 Mar; 26(3):390-399.e5. PubMed ID: 30612951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ABC of protein kinase conformations.
    Möbitz H
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1555-66. PubMed ID: 25839999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments.
    Zhang Q; Zhang X; You Q
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?
    Zhao Z; Wu H; Wang L; Liu Y; Knapp S; Liu Q; Gray NS
    ACS Chem Biol; 2014 Jun; 9(6):1230-41. PubMed ID: 24730530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
    Zhao H; Huang D; Caflisch A
    ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling conformational flexibility of kinases in inactive states.
    Schwarz D; Merget B; Deane C; Fulle S
    Proteins; 2019 Nov; 87(11):943-951. PubMed ID: 31168936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein kinase inhibitors: contributions from structure to clinical compounds.
    Johnson LN
    Q Rev Biophys; 2009 Feb; 42(1):1-40. PubMed ID: 19296866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
    Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
    J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of novel dasatinib analogues as potent DDR1 and DDR2 kinase inhibitors.
    Liu L; Hussain M; Luo J; Duan A; Chen C; Tu Z; Zhang J
    Chem Biol Drug Des; 2017 Mar; 89(3):420-427. PubMed ID: 27589335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
    Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
    Elife; 2020 Nov; 9():. PubMed ID: 33226337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Proteometric Analysis of Human Kinome: Insight into Discriminant Conformation-dependent Residues.
    Bosc N; Wroblowski B; Aci-Sèche S; Meyer C; Bonnet P
    ACS Chem Biol; 2015 Dec; 10(12):2827-40. PubMed ID: 26411811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting inactive conformations of protein kinases using active structures: conformational selection of type-II inhibitors.
    Xu M; Yu L; Wan B; Yu L; Huang Q
    PLoS One; 2011; 6(7):e22644. PubMed ID: 21818358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redefining the Protein Kinase Conformational Space with Machine Learning.
    Ung PM; Rahman R; Schlessinger A
    Cell Chem Biol; 2018 Jul; 25(7):916-924.e2. PubMed ID: 29861272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors.
    Ung PM; Schlessinger A
    ACS Chem Biol; 2015 Jan; 10(1):269-78. PubMed ID: 25420233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Affinity reagents that target a specific inactive form of protein kinases.
    Ranjitkar P; Brock AM; Maly DJ
    Chem Biol; 2010 Feb; 17(2):195-206. PubMed ID: 20189109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 2 inhibitor leads of human tropomyosin receptor kinase (hTrkA).
    Subramanian G; Bowen SJ; Zhu Y; Roush N; Zachary T; Javens C; Williams T; Janssen A; Gonzales A
    Bioorg Med Chem Lett; 2019 Oct; 29(19):126624. PubMed ID: 31444087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspective on computational and structural aspects of kinase discovery from IPK2014.
    Martin E; Knapp S; Engh RA; Moebitz H; Varin T; Roux B; Meiler J; Berdini V; Baumann A; Vieth M
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1595-604. PubMed ID: 25861861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis, and Evaluation of Dasatinib-Amino Acid and Dasatinib-Fatty Acid Conjugates as Protein Tyrosine Kinase Inhibitors.
    Tiwari RK; Brown A; Sadeghiani N; Shirazi AN; Bolton J; Tse A; Verkhivker G; Parang K; Sun G
    ChemMedChem; 2017 Jan; 12(1):86-99. PubMed ID: 27875633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure of mitogen-activated protein kinase kinase 1 in the DFG-out conformation.
    Nakae S; Kitamura M; Fujiwara D; Sawa M; Shirai T; Fujii I; Tada T
    Acta Crystallogr F Struct Biol Commun; 2021 Dec; 77(Pt 12):459-464. PubMed ID: 34866601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.